Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR8 | Q9NR97 | 4/20 | 0.57 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.45 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.44 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.43 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.36 |
| ▸ | SMOX | Q9NWM0 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 3/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | HPGD | P15428 | 3/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.35 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.34 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.34 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | AR | P10275 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12780756 | 0.83 | TLR8 (0.67) | TLR8MAPTKDM4ESMN1; SMN2HSD11B1 | |
| SCHEMBL3370644 | 0.81 | TLR8 (0.41) | TLR8MAPTKDM4ESMN1; SMN2HSD11B1 | |
| SCHEMBL3367910 | 0.78 | TLR8 (0.55) | TLR8MAPTKDM4ESMN1; SMN2HSD11B1 | |
| SCHEMBL12122765 | 0.76 | TLR8 (0.58) | TLR8MAPTKDM4ESMN1; SMN2HSD11B1 | |
| SCHEMBL3370903 | 0.76 | TLR8 (0.56) | TLR8MAPTKDM4ESMN1; SMN2HSD11B1 | |
| SCHEMBL6177743 | 0.75 | TLR8 (0.56) | TLR8MAPTKDM4EHSD11B1BCL2L1 | |
| SCHEMBL22169507 | 0.75 | HSD11B1 (0.57) | TLR8MAPTKDM4EHSD11B1BCL2L1 | |
| SCHEMBL2628123 | 0.74 | TLR8 (0.56) | TLR8MAPTKDM4ESMN1; SMN2HSD11B1 | |
| SCHEMBL11508991 | 0.73 | TLR8 (0.52) | TLR8MAPTKDM4ESMN1; SMN2HSD11B1 | |
| SCHEMBL3364662 | 0.73 | TLR8 (0.50) | TLR8MAPTKDM4ESMN1; SMN2HSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2266960-B1 | Aryl-substituted pyrazoles, imidazoles, oxazoles, thiazoles and pyrroles as anticonvulsants | EURO CELTIQUE SA (LU) | 2014-01-22 | — | — | EP | disclosed |
| EP-2266960-A2 | Aryl-substituted pyrazoles, imidazoles, oxazoles, thiazoles and pyrroles as anticonvulsants | EURO-CELTIQUE S.A. (LU) | 2010-12-29 | — | — | EP | disclosed |
| EP-1173169-B1 | ARYL SUBSTITUTED PYRAZOLES, IMIDAZOLES, OXAZOLES, THIAZOLES AND PYRROLES, AND THE USE THEREOF | EURO CELTIQUE SA (LU) | 2010-05-12 | — | — | EP | disclosed |
| EP-1173169-A4 | ARYL SUBSTITUTED PYRAZOLES, IMIDAZOLES, OXAZOLES, THIAZOLES AND PYRROLES, AND THE USE THEREOF | EURO CELTIQUE SA (LU) | 2007-04-04 | — | — | EP | disclosed |
| US-6737418-B2 | CENTRAL NERVOUS SYSTEM DISORDERS; ANTICONVULSANTS | EURO-CELTIQUE S.A. (LU) | 2004-05-18 | — | — | US | disclosed |
| US-20030069292-A1 | Aryl substituted pyrazoles, imidazoles, oxazoles, thiazoles and pyrroles, and the use thereof | EURO-CELTIQUE S.A. | 2003-04-10 | — | — | US | disclosed |
| US-6414011-B1 | CENTRAL NERVOUS SYSTEM DISORDERS | EURO-CELTIQUE S.A. (LU) | 2002-07-02 | — | — | US | disclosed |
| EP-1173169-A1 | ARYL SUBSTITUTED PYRAZOLES, IMIDAZOLES, OXAZOLES, THIAZOLES AND PYRROLES, AND THE USE THEREOF | Euro-Celtique S.A. (LU) | 2002-01-23 | — | — | EP | disclosed |
| WO-2000057877-A1 | ARYL SUBSTITUTED PYRAZOLES, IMIDAZOLES, OXAZOLES, THIAZOLES AND PYRROLES, AND THE USE THEREOF | EURO-CELTIQUE S.A. (LU) | 2000-10-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030069292-A1 | Aryl substituted pyrazoles, imidazoles, oxazoles, thiazoles and pyrroles, and the use thereof | GRIK5, GRIN3A, GRIK3 | TLR8 2722/4885MAPT 454/4885KDM4E 2557/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.